Order of the General Court of 3 September 2014 — Shire Pharmaceutical Contracts v Commission
(Case T-583/13) 1
(Action for annulment — Medicinal products for paediatric use — Regulation (EC) No 1901/2006 — Article 37 — Extension of the period of market exclusivity of off-patent orphan medicinal products — Act not amenable to review — Inadmissibility)
Language of the case: English
Parties
Applicant: Shire Pharmaceutical Contracts Ltd (Hampshire, United Kingdom) (represented by: K. Bacon, Barrister, M. Utges Manley and M. Vickers, Solicitors)
Defendant: European Commission (represented by: A. Sipos and V. Walsh, acting as Agents)
Re:
Application for the annulment of the decision purportedly contained in the letter which the Commission sent to the applicant on 2 September 2013, as subsequently confirmed by the letter of 18 October 2013, concerning whether the medicinal product Xagrid was eligible for the reward provided for in Article 37 of Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (OJ 2006 L 378, p. 1)
Operative part of the order
1. The action is dismissed as inadmissible.
2. Shire Pharmaceutical Contracts Ltd is ordered to pay the costs.
________________________1 OJ C 377, 21.12.2013.